Carprogesic 100 mg Tablets for Dogs

Ülke: Birleşik Krallık

Dil: İngilizce

Kaynak: VMD (Veterinary Medicines Directorate)

Aktif bileşen:

Carprofen

Mevcut itibaren:

Norbrook Laboratories Limited

ATC kodu:

QM01AE91

INN (International Adı):

Carprofen

Farmasötik formu:

Tablet

Reçete türü:

POM-V - Prescription Only Medicine – Veterinarian

Terapötik grubu:

Dogs

Terapötik alanı:

Anti Inflammatory NSAID

Yetkilendirme durumu:

Expired

Yetkilendirme tarihi:

2009-08-05

Ürün özellikleri

Revised: August 2014
AN. 00392/2013
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Carprogesic 100 mg Tablets for Dogs. (UK, AT, BE, DE, EL, FR, IE, LU,
NL,
PT, ES)
Profenacarp 100 mg Tablets for Dogs. (IT)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
Active Ingredient:
Carprofen
100 mg
Excipients:
Tartrazine (E102)
1.2 mg
For the full list of excipients, see Section 6.1
3.
PHARMACEUTICAL FORM
Tablet
A yellow circular tablet of 8 mm diameter, embossed “100” on one
side and a
single breakline on the other side.
The tablets can be divided into halves.
4.
CLINICAL PARTICULARS
4.1
_TARGET SPECIES:_
Dogs
4.2
_INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES:_
In the dog:
Reduction of inflammation and pain caused by musculoskeletal disorders
and
degenerative joint disease. As a follow up to parenteral analgesia in
the
management of post operative pain.
4.3
_CONTRAINDICATIONS:_
Do not use in cats.
Do not use in pregnant or lactating bitches.
Do not use in puppies less than 4 months of age.
Do not use in animals with known hypersensitivity to the active
substance or
to any of the excipients
Revised: August 2014
AN. 00392/2013
Page 2 of 5
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where
there is a possibility of gastrointestinal ulceration or bleeding, or
where there is
evidence of a blood dyscrasia.
4.4
_SPECIAL WARNINGS FOR EACH TARGET SPECIES:_
Refer to Sections 4.3 and 4.5.
4.5
_SPECIAL PRECAUTIONS FOR USE:_
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use in aged dogs may involve additional risk.
If such a use cannot be avoided, such dogs may require a reduced
dosage
and careful clinical management.
Avoid use in any dehydrated, hypoproteinemic, hypovolaemic or
hypotensive
dog, as there is a potential risk of increased renal toxicity.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment
of
inflammatory
conditions
associated
with
bacterial
infection,
appropriate
concurrent antimicrobial therapy should be instiga